SLGL - Sol-Gel Technologies Ltd.
IEX Last Trade
1.115
0.040 3.587%
Share volume: 15,557
Last Updated: Thu 26 Dec 2024 08:30:01 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$1.08
0.04
3.72%
Fundamental analysis
22%
Profitability
25%
Dept financing
11%
Liquidity
50%
Performance
15%
Performance
5 Days
-40.62%
1 Month
70.10%
3 Months
38.00%
6 Months
8.87%
1 Year
-24.63%
2 Year
-78.23%
Key data
Stock price
$1.12
DAY RANGE
$0.88 - $1.12
52 WEEK RANGE
$0.38 - $1.65
52 WEEK CHANGE
-$21.62
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Alon Seri-Levy
Region: US
Website: sol-gel.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: sol-gel.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Sol-Gel Technologies Ltd. focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system. Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris, Epsolay, SGT-210, and Erlotinib, Tapinarof, and roflumilast are the company's lead product candidates.
Recent news